AVMA Voices Concerns About DEA Scheduling Process

Drug availability continues to be top of mind for AVMA members, and availability of controlled substances, including anesthetic drugs, is no exception. The AVMA’s Council on Biologic and Therapeutic Agents and its Clinical Practitioners Advisory Committee recently recommended AVMA submit to the Drug Enforcement Administration (DEA) a letter conveying our concerns about the DEA’s scheduling process reportedly being a barrier to innovation and drug availability. A specific concern that came to AVMA from the American College of Anesthesia and Analgesia is the unavailability of an induction agent approved by the Food and Drug Administration in September 2012. The AVMA understands that this particular drug is still going through DEA’s scheduling process and is consequently not yet commercially available for use in the USA.  

AVMA continues to monitor ways to advocate for members on drug availability, and we are working daily on these issues. We likewise appreciate members sharing drug availability concerns with AVMA so that we can follow up on these and other issues relevant to veterinarians.

Comments are closed.